Daniel Bradbury - 27 Jul 2026 Form 4 Insider Report for Vivani Medical, Inc. (VANI)

Reporting relationship: Director
Issuer ticker: VANI
Reported as of: 27 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2026, 18:48:15 UTC
Prior SEC filing: 25 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Anthony Baldor, Attorney-in-fact

Key filing fact

Daniel Bradbury filed Form 4 for Vivani Medical, Inc. (VANI) on 28 Jul 2026.

Key facts

This page summarizes Daniel Bradbury's Form 4 filing for Vivani Medical, Inc. (VANI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jul 2026, 18:48.

Change

Previous filing in this sequence was filed on 25 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001236397 Primary reporting owner

BRADBURY DANIEL

Relationship: Director
Address: C/O VIVANI MEDICAL, INC., 1350 S. LOOP ROAD, ALAMEDA
Signature: /s/ Anthony Baldor, Attorney-in-fact
Signature date: 28 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VANI transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value
Shares: +7,965
Change %
Price: $1.30^*
Shares after: 7,965
Date: 27 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,965
Exercise price: $1.30
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date.

Footnote F2

Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service.